Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q3 2024 · 10-Q
Revenue$614.24K$614.24K+0.5% vs Q3 2023 Net Income-$436.67K-$436.67KN/M vs Q3 2023 EPS Diluted-$0.28-$0.28N/M vs Q3 2023 Operating Income-$499,473N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-81.3%+106.3 pt vs Q3 2023
Net margin-71.1%+101.6 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end